AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28341619
Drug: Waitlist (WL)
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Waitlist (WL) control plus usual treatment
Trial: 22906798
Drug: Lithium monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium monotherapy (initial dose: 600mg/d, adjusted to therapeutic levels)
Trial: 17150416
Drug: Monoimmunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoimmunotherapy with interferon‐alpha applied three times weekly for a total of 4 weeks
Trial: 15520346
Drug: Vaccine offered
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine offered group
Trial: 11281461
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Trial: 11281461
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Trial: 9771866
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg Ca/d as calcium citrate malate)
Trial: 7787753
Drug: All transretinoic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All transretinoic acid (ATRA) combined with intensive chemotherapy
Trial: 2159696
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g sodium propionate daily in capsule form
Trial: 6784978
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg infused over 3 h)
Trial: 28892457
Drug: Romosozumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (210 mg monthly for 12 months)
Trial: 23024190
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg weekly for 12 months)
Trial: 20940517
Drug: C‐G‐A‐A‐A‐C‐C haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐G‐A‐A‐A‐C‐C haplotype
Trial: 19217717
Drug: Orthopaedic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopaedic manual therapy and exercise programme (OMTP)
Trial: 2402207
Drug: Glycerol (1
RxNorm normalized name: GLYCEROL (1-(12-HYDROXYSTEARATE))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol (1 g.kg‐1 body weight) plus water (21.4 ml.kg‐1 body weight)
Trial: 2402207
Drug: Water (21.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (21.4 ml.kg‐1)
Trial: 2402207
Drug: Water (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (3.3 ml.kg‐1)
Trial: 26100
Drug: Electropupillogram (E.P.G.)
RxNorm normalized name: E.S.P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electropupillogram (E.P.G.) test dose of stimulant
Trial: 28281731
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin
Trial: 28237426
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy (GT) with a second subretinal injection in the contralateral eye
Trial: 21803971
Drug: Intravenous hypotension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypotension
Trial: 16275807
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g/d)
Trial: 9456664
Drug: Orapette SalivaCard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orapette SalivaCard HIV‐1/HIV‐2 antibody test
Trial: 7695268
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of piperacillin-tazobactam (50 mg/kg piperacillin and 6.25 mg/kg tazobactam)
Trial: 7695268
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of piperacillin-tazobactam (100 mg/kg piperacillin and 12.5 mg/kg tazobactam)
Trial: 7695268
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of piperacillin-tazobactam
Trial: 29725975
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (Familact®)
Trial: 23897021
Drug: 1.25 g·d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g·d of PEG‐creatine
Trial: 23897021
Drug: 2.50 g·d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.50 g·d of PEG‐creatine
Trial: 12499329
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lysine x kg(‐1) x d(‐1)
Trial: 12499329
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg lysine x kg(‐1) x d(‐1)
Trial: 12499329
Drug: 36 mg
RxNorm normalized name: pyrantel 136 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg lysine x kg(‐1) x d(‐1)
Trial: 12499329
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg lysine x kg(‐1) x d(‐1)
Trial: 12499329
Drug: 42 mg
RxNorm normalized name: lithium 42 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 mg lysine x kg(‐1) x d(‐1)
Trial: 10660004
Drug: 60 mEq
RxNorm normalized name: phosphorus 45 MMOL / sodium 60 MEQ per 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mEq supplemental oral potassium daily
Trial: 8646351
Drug: Intraperitoneal kanamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal kanamycin (500 mg)
Trial: 6650492
Drug: DDAVP and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP and intravenous fluids
Trial: 6650492
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and intravenous fluids
Trial: 29422023
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy delivered by trained and supervised lay health workers (6 sessions)
Trial: 19594194
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs) - olanzapine, quetiapine, risperidone, ziprasidone
Trial: 19594194
Drug: First-generation antipsychotic
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotic (FGA) - perphenazine
Trial: 19594194
Drug: First-generation antipsychotic
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) in CUtLASS
Trial: 17475943
Drug: Prednisolone 60
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60 mg on days 1 and 2, 40 mg on days 3 and 4, and 20 mg on days 5 and 6 (Group A)
Trial: 17475943
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 6 days (Group B)
Trial: 2694509
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of mefloquine/sulfadoxine/pyrimethamine (MSP)
Trial: 30851699
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment for 9 weeks (specifics not provided)
Trial: 25271009
Drug: Sucralose (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (24 mg in 200 ml of water)
Trial: 25271009
Drug: Aspartame (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (72 mg in 200 ml of water)
Trial: 7647826
Drug: Water (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (200 ml)
Trial: 23589672
Drug: Interleukin-7 (IL-7)
RxNorm normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-7 (IL-7) administered to virally suppressed subjects
Trial: 19552904
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, 3 times per day for 2 cycles)
Trial: 17926620
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of 2000 microg of VitB12
Trial: 17926620
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Carbamazepine
Trial: 15529370
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg daily)
Trial: 11574913
Drug: 6-day dose
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-day dose escalation of TMP-SMZ
Trial: 7836551
Drug: co‐trimoxazole 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co‐trimoxazole 160/800 mg twice a day
Trial: 28380062
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1700 mL infused)
Trial: 28380062
Drug: Gelatine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine 4% (1500 mL infused)
Trial: 28380062
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (HES) 6% (1500 mL infused)
Trial: 28380062
Drug: Albumin 5%
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin 5% (1500 mL infused)
Trial: 12743981
Drug: Pegylated-liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated-liposomal doxorubicin (Doxil™) at an initial dose of 55 mg/m2 every four weeks
Trial: 8882073
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (250 micrograms) inhaled terbutaline
Trial: 8882073
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (1000 micrograms) inhaled terbutaline
Trial: 1348219
Drug: Formoterol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (4 x 6 micrograms twice a day and as necessary, n = 19)
Trial: 1348219
Drug: Salbutamol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (4 x 100 micrograms twice a day and as necessary, n = 16)
Trial: 3987793
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg 8 hourly
Trial: 3987793
Drug: Nadolol 80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 80 mg with Nifedipine 20 mg
Trial: 24725763
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with atorvastatin (20mg/day) and ezetimibe (10mg/day)
Trial: 24725763
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with atorvastatin alone
Trial: 20930431
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg/day) + alfacalcidol (0.25 µg/day)
Trial: 20930431
Drug: Alfacalcidol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.25 µg/day) alone
Trial: 15951474
Drug: Long-acting octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting octreotide 20 mg
Trial: 15951474
Drug: Long-acting octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting octreotide 60 mg
Trial: 15951474
Drug: Prolonged-release lanreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release lanreotide 90 mg
Trial: 15951474
Drug: Prolonged-release lanreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release lanreotide 120 mg
Trial: 10325895
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 micrograms twice daily plus the run in dose of fluticasone propionate
Trial: 10325895
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the dose of fluticasone propionate (200 or 500 micrograms twice daily)
Trial: 30819358
Drug: Prasugrel pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel pre-treatment
Trial: 29077022
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g per day for six days)
Trial: 31669625
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg/day)
Trial: 24550580
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg/day) plus bromocriptine (0.8 mg/day)
Trial: 24550580
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg/day) plus bromocriptine (1.6 mg/day)
Trial: 22106246
Drug: High-volume fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume fluid therapy (10 mL/kg/h)
Trial: 22106246
Drug: Low-volume fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume fluid therapy (4 mL/kg/h)
Trial: 17704795
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care group (CC)
Trial: 12499786
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 200mg IV q 12 hours for 3 days
Trial: 7796076
Drug: Insulin Tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Tolerance Test (ITT)
Trial: 31296300
Drug: On-treatment TIMI
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment TIMI major bleeding in patients with diabetes
Trial: 27087507
Drug: Propiverine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine ER 30 mg
Trial: 23351597
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (capsule) of levodropropizine 60 mg
Trial: 23351597
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (syrup) of levodropropizine 60 mg
Trial: 23351597
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (capsule and syrup)
Trial: 11057790
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg) - 0 doses
Trial: 11057790
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg) - 1 dose
Trial: 11057790
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg) - 2 doses
Trial: 11057790
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg) - 3 doses
Trial: 11057790
Drug: Prenatal corticosteroid
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal corticosteroid treatment
Trial: 2000045
Drug: methionyl recombinant
RxNorm normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methionyl recombinant human growth hormone (met‐hGH) 0.06 IU/kg
Trial: 6393665
Drug: Standardized therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized therapy
Trial: 31490424
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg CAF + 100 mg CA
Trial: 29310688
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day EPA/DHA
Trial: 29310688
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day EPA/DHA
Trial: 29310688
Drug: EPA/DHA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA therapy
Trial: 22214903
Drug: Zolpidem (GABARα1-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (GABARα1-selective agonist)
Trial: 15165934
Drug: losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 100 mg/day
Trial: 20588058
Drug: candesartan 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan 12 mg/day
Trial: 20588058
Drug: olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan 40 mg/day
Trial: 22108775
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily
Trial: 10594527
Drug: 0.3 mg/day
RxNorm normalized name: cloNIDine HCl 0.3 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/day conjugated equine oestrogens (CEE)
Trial: 10594527
Drug: 0.6 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/day conjugated equine oestrogens (CEE)
Trial: 10594527
Drug: 1.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/day conjugated equine oestrogens (CEE)
Trial: 10594527
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of CEE
Trial: 2085344
Drug: Acamprosate (CA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (CA), 1.3 g/day
Trial: 28278602
Drug: CBT-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-only treatment (ACTION Treatment; Stark et al., 2006)
Trial: 28666535
Drug: Childcare intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Childcare intervention alone (CC)
Trial: 22030047
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) followed by misoprostol (100 μg or 50 μg)
Trial: 22030047
Drug: Misoprostol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (100 μg or 50 μg) alone
Trial: 17453591
Drug: Structured interrupted
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured interrupted therapy (SIT)
Trial: 29684092
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (CT)
Trial: 12377961
Drug: No immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunotherapy (control)
Trial: 9840563
Drug: Daily conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily conjugated equine estrogens
Trial: 9840563
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens plus daily medroxyprogesterone acetate
Trial: 7856287
Drug: Mumps vaccine,
RxNorm normalized name: mumps vaccine,live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mumps vaccine, strain Sofia 6
Trial: 26394259
Drug: +IN-βG yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +IN-βG yogurt (1.9 g of inulin and 0.5 g of β-glucan)
Trial: 26394259
Drug: Fibre-enriched formulations
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-enriched formulations (2.4 g of inulin and 0.5 g of β-glucan)
Trial: 26394259
Drug: Yogurt with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt with 0.5 g of β-glucan
Trial: 21241922
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg, 3 times daily for 7 days (2 days before and 4 days after surgery)
Trial: 21241922
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times daily for 7 days (2 days before and 4 days after surgery)
Trial: 19225118
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fat infusion)
Trial: 10857213
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) 2 mg daily in combination with ethinylestradiol (EE2) 35 mg or 50 mg
Trial: 10857213
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) 2 mg daily
Trial: 9088884
Drug: Oral SRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SRI drugs (standardized treatment for 10 weeks)
Trial: 8256902
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (2.5 mg)
Trial: 8256902
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (7.5 mg cumulative dose)
Trial: 8256902
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (15.0 mg cumulative dose)